Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Durect Corporation To Present Preliminary Data From The Ongoing Dur-928 Alcoholic Hepatitis Phase 2a Trial And Report First Quarter 2019 Financial Results
Venture Capital

Durect Corporation To Present Preliminary Data From The Ongoing Dur-928 Alcoholic Hepatitis Phase 2a Trial And Report First Quarter 2019 Financial Results

by prnewswire.com posted 2months ago 264 views
CUPERTINO, Calif., May 3, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report preliminary data from the ongoing DUR-928 alcoholic hepatitis (AH) trial and its financial results for the three months ended March 31, 2019 after the market close on...